BICO Group — Cyborg Score 7/10

Strong
Biotech/Life Sciences Infrastructure - 3D Bioprinting, Lab Automation & Cell Culture

Strategic Profile

BICO transitioned to a bioconvergence company in 2020, expanding its focus from bioprinting to broader life sciences technology and industrial solutions. Operating through three business areas – Bioprinting, Biosciences and Bioautomation – the BICO Group strives towards the long-term ambition of enabling the reduction of the world's organ shortage and speeding up drug development. BICO is a prominent player in the global 3D bioprinting market, boasting a diversified portfolio of products for 3D cell cultures for high-throughput drug screening and printing of human tissues and organs.

Cyborg Score Rationale

BICO holds a clear market leadership position in 3D bioprinting with extensive institutional adoption across pharma and academic labs. Strategic acquisition strategy (MatTek, Nanoscribe, Biosero, Advanced BioMatrix) has broadened the platform. However, past management controversies and execution risks on bioconvergence integration temper the outlook.

Top Insights

  • BICO has 32,000+ instruments installed across 65+ countries deployed in 3,500+ laboratories including world's top 20 pharma companies with 11,000+ academic citations
  • BICO operates through Lab Automation and Life Science Solutions business areas, striving toward automating the life science lab of the future
  • Sartorius acquired 10% stake in BICO for €45 million with strategic collaboration on R&D and digital solutions, validating growth strategy
  • Maria Forss was appointed as CEO in August 2023 following transition from founder Erik Gatenholm

Named Competitors

  • 3D Bioprinting Systems — US-based 3D printing and bioprinting solutions provider with strong pharma partnerships
  • Bioprinting Technology — US-based company focused on 3D bioprinted tissues for drug discovery
  • Lab Automation & Bioreactors — German biopharmaceutical equipment supplier with 10% BICO stake and strategic partnership

Recent Developments

  • (August 2023) New CEO Maria Forss appointed, replacing co-founder Erik Gatenholm
  • (2023) Sartorius acquired 10% strategic stake for €45M with comprehensive technology partnership
  • (May 2023) Launched third-generation LUMEN X bioprinter for high-resolution DLP bioprinting

Open the full interactive BICO Group report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →